Compare · KROS vs LLY
KROS vs LLY
Side-by-side comparison of Keros Therapeutics Inc. (KROS) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KROS and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 5226.8x KROS ($203.9M).
- Over the past year, KROS is down 28.9% and LLY is up 48.6% - LLY leads by 77.6 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 12 for KROS).
- LLY has more recent analyst coverage (25 ratings vs 22 for KROS).
- Company
- Keros Therapeutics Inc.
- Eli Lilly and Company
- Price
- $10.01-2.72%
- $1149.79+1.50%
- Market cap
- $203.9M
- $1.07T
- 1M return
- -13.86%
- +17.88%
- 1Y return
- -28.93%
- +48.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 12
- 17
- Recent ratings
- 22
- 25
Keros Therapeutics Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest KROS
- Director Farzan Nima sold $28,166 worth of shares (2,625 units at $10.73) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 9,767 units (SEC Form 4)
- Director Knowles Julius sold $28,166 worth of shares (2,625 units at $10.73) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 10,958 units (SEC Form 4)
- Director Seth Alpna was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Seth Alpna sold $28,140 worth of shares (2,625 units at $10.72) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 9,767 units (SEC Form 4)
- Director Gray Mary Ann was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Farzan Nima was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Bienaime Jean Jacques was granted 7,142 shares, increasing direct ownership by 76% to 16,592 units (SEC Form 4)
- Director Knowles Julius was granted 7,142 shares, increasing direct ownership by 111% to 13,583 units (SEC Form 4)
- Keros Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Keros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest LLY
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets